Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling
Phuong Doan1,2,3, Aliyu Musa1,2,3, Akshaya Murugesan1,2,4
1Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 553, 33101 Tampere, Finland.
Abstract:
Cancer stem cells (CSCs), a small subpopulation of cells existing in the tumor microenvironment promoting cell proliferation and growth. Targeting the stemness of the CSC population would offer a vital therapeutic opportunity. 3,4-Dihydroquinolin-1(2H)-yl)(p-tolyl)methyl)phenol (THTMP), a small synthetic phenol compound, is proposed to play a significant role in controlling the CSC proliferation and survival. We assessed the potential therapeutic effects of THTMP on glioblastoma multiforme (GBM) and its underlying mechanism in various signaling pathways. To fully comprehend the effect of THTMP on the CSCs, CD133+ GBM stem cell (GSC) and CD133- GBM Non-stem cancer cells (NSCC) population from LN229 and SNB19 cell lines was used. Cell cycle arrest, apoptosis assay and transcriptome analysis were performed for individual cell population. THTMP strongly inhibited NSCC and in a subtle way for GSC in a time-dependent manner and inhibit the resistance variants better than that of temozolomide (TMZ). THTMP arrest the CSC cell population at both G1/S and G2/M phase and induce ROS-mediated apoptosis. Gene expression profiling characterize THTMP as an inhibitor of the p53 signaling pathway causing DNA damage and cell cycle arrest in CSC population. We show that the THTMP majorly affects the EGFR and CSC signaling pathways. Specifically, modulation of key genes involved in Wnt, Notch and Hedgehog, revealed the significant role of THTMP in disrupting the CSCs' stemness and functions. Moreover, THTMP inhibited cell growth, proliferation and metastasis of multiple mesenchymal patient-tissue derived GBM-cell lines. THTMP arrests GBM stem cell cycle through the modulation of EGFR and CSC signaling pathways.
Insights
The synthetic phenol THTMP effectively targets cancer stem cells (CSCs) in glioblastoma, inhibiting proliferation and inducing apoptosis. THTMP shows promise as a therapeutic agent, outperforming temozolomide in certain resistance variants.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Stem Cell Research
Background:
- Cancer stem cells (CSCs) drive tumor growth and therapeutic resistance.
- Targeting CSC stemness is a critical therapeutic strategy.
- Glioblastoma multiforme (GBM) presents significant treatment challenges due to its heterogeneous cell populations.
Purpose of the Study:
- To evaluate the therapeutic potential of the synthetic phenol THTMP against GBM.
- To elucidate the mechanisms by which THTMP affects CSCs and non-stem cancer cells (NSCCs).
- To assess THTMP's efficacy compared to temozolomide (TMZ) in GBM models.
Main Methods:
- Utilized CD133+ GBM stem cells (GSCs) and CD133- NSCCs from LN229 and SNB19 cell lines.
- Performed cell cycle analysis, apoptosis assays, and transcriptome analysis.
- Investigated the impact of THTMP on key signaling pathways including p53, EGFR, Wnt, Notch, and Hedgehog.
Main Results:
- THTMP inhibited both GSCs and NSCCs in a time-dependent manner, with notable efficacy against resistant variants compared to TMZ.
- THTMP induced G1/S and G2/M cell cycle arrest and promoted ROS-mediated apoptosis in CSCs.
- Gene expression profiling revealed THTMP's inhibition of the p53 pathway, leading to DNA damage and cell cycle arrest, and its modulation of EGFR and CSC-related pathways.
Conclusions:
- THTMP demonstrates significant anti-cancer effects on GBM by targeting CSC stemness and proliferation.
- THTMP disrupts critical CSC signaling pathways (Wnt, Notch, Hedgehog) and modulates EGFR signaling.
- THTMP represents a promising therapeutic candidate for GBM, particularly against resistant cell populations.
More Related Videos
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
